Abbott's hepatitis C drugs perform well in 2 small trials

04/4/2012 | Wall Street Journal, The

A midstage trial showed that Abbott Laboratories' protease inhibitor ABT-450, in combination with polymerase inhibitor ABT-333 and existing drug ribavirin, suppressed the hepatitis C virus 12 weeks after treatment ended in more than 90% of treatment-naive patients and 47% of patients who didn't respond to prior treatment. In another Phase II study, 10 of 11 patients who received ABT-450 along with Abbott's polymerase inhibitor ABT-072 and ribavirin showed a sustained virologic response 24 weeks after treatment ended. Abbott hopes to take forward some combination of the drugs used in the studies into Phase III testing next year.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA